Finder

Current NHS consultant posts held

Consultant at Guys Hospital and Kings Hospital London

Research interests

Novel agents in breast cancer

Personal interests

Football, skiing, family

Publications

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. (2016)
Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Nathan MR, Wotherspoon A, Gao Z, Shi Y, Eynden G, Salman A, Lazaris A, Daley F, Gazinska P, Berg T, Eltahir Z, Peckitt C, Ritsma L, Rheenen J, Khashper A, Brown G, Nystrom N, Sund M, Van Laere S, Loyer E, Dirix L, Metrakos P, Cunningham D, Reynolds A.
Nature Medicine: 22: 1294-1302 (2016)

Abstract 4105: Dissecting the mechanisms of hepatocyte replacement in breast cancer liver metastases (2016)
Nathan MR, Kostaras L, Bridgeman VL, Foo S, Vermeulen PB, Reynolds AR
Cancer Research 76 (14 Supplement):4105-4105 · July 2016

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. (2016)
Bridgeman V, Vermeulen P, Foo S, Bilecz A, Kostaras E, Daley F, Nathan MR, Wan E, Frentzas S, SchweigerT, Hegedus B, Vasudev N, Larkin J, Gore M, Dvorak H, Paku S, Kerbel R, Dome B, Reynolds A
The Journal of Pathology: 241(3): 362-374 (2016)

Preclinical evidence that trametinib enhances the response to anti-angiogenic tyrosine kinase inhibitors in renal cell carcinoma. (2015)
Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N, Springer CJ, Powles T, Nathan P, Larkin J, Gore M, Vasudev NS, Reynolds AR.
Molecular Cancer Therapeutics 15(1):1-12 2015

A review of fulvestrant in breast cancer
Nathan MR, Schmid P
Oncology and Therapy March 2017

The emerging world of breast cancer immunotherapy
Nathan MR, Schmid P
The Breast June 2017